Skip to content

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy: a Multicenter, Randomized, Controlled Clinical Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05291325
Enrollment
1607
Registered
2022-03-22
Start date
2022-05-25
Completion date
2024-04-28
Last updated
2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel Preparation for Colonoscopy

Keywords

Linaclotide, Bowel preparation, colonoscopy

Brief summary

The clinical purpose of this study was to investigate whether the adjuvant application of linaclotide in bowel preparation for colonoscopy could improve the quality of bowel preparation or reduce the dosage of laxatives.

Interventions

DRUG3L PEG + Linaclotide

Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

DRUG3L PEG

Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

DRUG2L PEG + Linaclotide

Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.

Sponsors

Shanxi Provincial People's Hospital
CollaboratorOTHER_GOV
900 Hospital of Joint Logistics Support Force of PLA
CollaboratorOTHER
Ruijin Hospital
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
The Affiliated Hospital of Qingdao University
CollaboratorOTHER
The Third Affiliated Hospital of Wenzhou Medical University
CollaboratorOTHER
Affiliated Yueqing Hospital of Wenzhou Medical University
CollaboratorOTHER
The First Affiliated Hospital of Soochow University
CollaboratorOTHER
The 7th Medical Center of the PLA General Hospital
CollaboratorUNKNOWN
The First Hospital of Jilin University
CollaboratorOTHER
The Second Hospital of Hebei Medical University
CollaboratorOTHER
The Affiliated Hospital of Inner Mongolia Medical University
CollaboratorOTHER
The Second Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
Ningxia Medical University General Hospital
CollaboratorUNKNOWN
Affiliated Hospital of Qinghai University
CollaboratorOTHER
Yunnan First People's Hospital
CollaboratorUNKNOWN
Second Xiangya Hospital of Central South University
CollaboratorOTHER
Shanghai Zhongshan Hospital
CollaboratorOTHER
Daping Hospital, Army Military Medical University
CollaboratorUNKNOWN
Zunyi Medical College
CollaboratorOTHER
Huizhou Municipal Central Hospital
CollaboratorOTHER
Affiliated Hospital of Southwest Medical University
CollaboratorOTHER
The First Hospital of Shihezi University
CollaboratorUNKNOWN
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
Tangdu Hospital of Air Force Military Medical University
CollaboratorUNKNOWN
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-75 years old, male or female; * To undergo diagnostic, screening or monitoring colonoscopy; * Signed written informed consent;

Exclusion criteria

* Severe cardiopulmonary insufficiency, renal failure or a history of stroke or myocardial infarction within six months; * History of abdominal or pelvic surgery; * Pregnant and lactating women; * BMI \> 28, BMI \< 18.5, inflammatory bowel disease, constipation (defecation less than 3 times in the last week, and laborious defecation, fecal sclerosis, low volume) or intestinal obstruction and other high-risk factors of intestinal preparation; * Abnormal coagulation function or taking antiplatelet or anticoagulant drugs within 7 days; * Warning symptoms and signs of colorectal cancer: hematochezia, melena, unexplained anemia, low body weight, abdominal mass, positive digital rectal test; or imaging and laboratory tests highly suspect colorectal cancer; * Colon polyps have been identified; * Stow score 7 (watery, no solid mass), diarrhea was considered; * Participation in other interventional clinical trials within 60 days.

Design outcomes

Primary

MeasureTime frameDescription
Bowel preparation adequate ratewithin 10 minute after viewing colonoscopy video.The proportion of participants with all colon segment scores (right colon, transverse colon, left colon) were ≥ 2 according to Boston Bowel Preparation Scale (BBPS) .

Secondary

MeasureTime frameDescription
Aronchick ScaleWithin 10 minute after viewing colonoscopy video.Overall bowel preparation was scored prior to irrigation or suction. The Aronchick Scale scoring rules: 1, excellent, a small amount of liquid, 95% mucous membrane is visible; 2, good, plenty of clear fluid, covering 5%-25% of mucous membrane, 90% mucous membrane is visible; 3, medium, semi-solid manure that cannot be sucked out or washed away, 90% mucous membrane is visible; 4, poor, semi-solid manure that cannot be sucked out or washed away, 90% mucous membrane is visible; 5, inadequate, repeated bowel preparation or reexamination is required. Total Aronchick score 1-5, the lower the score, the better the quality of bowel preparation.
Bowel preparation excellent rateWithin 10 minute after viewing colonoscopy video.The proportion of participants with total score ≥ 8 according to Boston Bowel Preparation Scale.
Bowel preparation completion rate assessed by questionnaire surveyImmediately after questionnaire survey.Proportion of subjects with laxative intake greater than 90% of the required amount in protocol.
Subjects satisfaction rate assessed by questionnaire surveyImmediately after questionnaire survey.Proportion of subjects satisfacted with the whole intestinal preparation process. Subjects satisfaction was divided into four grades: 4, very satisfied; 3, moderately satisfied; 2, moderately dissatisfied; 1, very dissatisfied. Subjects in grades 3 and 4 were considered satisfied; subjects in grades 1 and 2 were considered dissatisfied.
Boston bowel preparation scale scoreWithin 10 minute after viewing colonoscopy video.The BBPS scoring rules: 0, unprepared colon segment with mucosa not seen because of solid stool that cannot be cleared; 1, portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid; 2, minor amount of residual staining, small fragments of stool, and/or opaque liquid, but mucosa of colon segment is seen well; 3, entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. the higher the score, the better the quality of bowel preparation. 3 intestinal segments were scored separately: the right side of the colon, the transverse section of the colon, and the left side of the colon. Total BBPS score 0-9, the higher the score, the better the quality of bowel preparation.
Adenoma detection rate14 days after colonosopy.The adenoma detection rate was calculated as the number of colonoscopies with at least one adenoma detected divided by the total number of colonoscopies in the group. Adenomatous polyps must be confirmed by pathological findings.
Polyp detection rateImmediately after colonoscopy.The polyp detection rate was calculated as the number of colonoscopies with at least one polyp detected divided by the total number of colonoscopies in the group.
Incidence of adverse events assessed by questionnaire surveyImmediately after questionnaire survey.Proportion of subjects with adverse events occuring in intestinal preparation.
Drug compliance in linaclotide groupImmediately after questionnaire survey.Proportion of subjects Taking 3 linaclotide capsules according to the protocol in linaclotide group.
Endoscopists satisfaction with the quality of bowel preparationImmediately after colonoscopy.Proportion of endoscopists satisfacted with the quality of bowel preparation during colonoscopy. Endoscopists satisfaction was divided into four grades: 4, very satisfied; 3, moderately satisfied; 2, moderately dissatisfied; 1, very dissatisfied. Subjects in grades 3 and 4 were considered satisfied; subjects in grades 1 and 2 were considered dissatisfied.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026